BeOne Medical Affairs shared a post on LinkedIn:
“A new publication in Oncology and Therapy evaluates real-world treatment patterns and outcomes among more than 10,000 Medicare beneficiaries with treatment-naïve chronic lymphocytic leukemia (CLL) receiving first-line Bruton tyrosine kinase (BTK) inhibitor therapy.
Dr. Daniel Ermann, lead author of the study, shares:
‘Real-world studies such as this one can help address important evidence gaps by providing insight into treatment patterns and outcomes among patients treated in routine clinical practice. I’m pleased to contribute to this analysis of older Medicare beneficiaries with treatment-naïve CLL receiving frontline covalent BTK inhibitor therapy.’
Title: Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL
Authors: Daniel A. Ermann, Deborah M. Stephens, Xiaoliang Wang, Irene Varghese, Heidi De Souza, Caitlin Sheetz, Qianhong Fu, Gregory A. Maglinte, Rhys Williams, Erlene K. Seymour, Derrick van Beuge, Mazyar Shadman and Ryan Jacobs.
Other articles about BeOne on OncoDaily.
